Related Experiment Video

Updated: Aug 24, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

New therapies for pneumococcal meningitis

P H Cottagnoud1, M G Täuber

  • 1Department of Internal Medicine, Inselspital, Bern, Switzerland. pcottagn@insel.ch

Expert Opinion on Investigational Drugs
|April 23, 2004
PubMed

Insights

New antibiotics show promise for treating pneumococcal meningitis, a challenging infection. Combination therapies are particularly effective against resistant bacteria in animal models.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Pneumococcal meningitis presents significant treatment challenges due to high morbidity and mortality.
  • Increasing resistance to penicillin, cephalosporins, and vancomycin compromises standard antibiotic efficacy.
  • Existing treatments are threatened by the rise of drug-tolerant pneumococcal strains.

Purpose of the Study:

  • To review newly developed antibiotics for treating pneumococcal meningitis.
  • To evaluate the efficacy of novel monotherapies and combination treatments.
  • To address the growing challenge of antibiotic resistance in pneumococcal meningitis.

Main Methods:

  • Testing of new antibiotics in a rabbit meningitis model.
  • Evaluation of newer beta-lactam monotherapies (cefepime, meropenem, ertapenem).
  • Assessment of novel quinolones (garenoxacin, gemifloxacin, gatifloxacin, moxifloxacin) and daptomycin.
  • Investigation of synergistic activity in combination treatments.

Main Results:

  • Several new beta-lactams, quinolones, and daptomycin were tested.
  • Newer agents demonstrated potential in preclinical models.
  • Combination therapies showed synergistic activity against resistant strains in the rabbit model.

Conclusions:

  • Novel antibiotics offer potential alternatives for pneumococcal meningitis treatment.
  • Combination therapies may be crucial for overcoming increasing antibiotic resistance.
  • Further research is warranted to translate these findings to clinical practice.

More Related Videos

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...